Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Targeted drug delivery systems mediated by a novel Peptide in breast cancer therapy and imaging.

Lu RM, Chen MS, Chang DK, Chiu CY, Lin WC, Yan SL, Wang YP, Kuo YS, Yeh CY, Lo A, Wu HC.

PLoS One. 2013 Jun 11;8(6):e66128. doi: 10.1371/journal.pone.0066128.

2.

Peptide-mediated liposomal Doxorubicin enhances drug delivery efficiency and therapeutic efficacy in animal models.

Chang DK, Li PC, Lu RM, Jane WN, Wu HC.

PLoS One. 2013 Dec 27;8(12):e83239. doi: 10.1371/journal.pone.0083239.

3.

Improved breast cancer cell-specific intracellular drug delivery and therapeutic efficacy by coupling decoration with cell penetrating peptide and SP90 peptide.

Fan LQ, Du GX, Li PF, Li MW, Sun Y, Zhao LM.

Biomed Pharmacother. 2016 Dec;84:1783-1791. doi: 10.1016/j.biopha.2016.10.102.

PMID:
27899251
4.

A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density.

Gray BP, McGuire MJ, Brown KC.

PLoS One. 2013 Aug 23;8(8):e72938. doi: 10.1371/journal.pone.0072938.

5.

Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.

Shahin M, Soudy R, El-Sikhry H, Seubert JM, Kaur K, Lavasanifar A.

Cancer Lett. 2013 Jul 1;334(2):284-92. doi: 10.1016/j.canlet.2012.10.007.

PMID:
23073474
6.

Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein.

Wang T, Hartner WC, Gillespie JW, Praveen KP, Yang S, Mei LA, Petrenko VA, Torchilin VP.

Nanomedicine. 2014 Feb;10(2):421-30. doi: 10.1016/j.nano.2013.08.009.

7.

Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.

Zahmatkeshan M, Gheybi F, Rezayat SM, Jaafari MR.

Eur J Pharm Sci. 2016 Apr 30;86:125-35. doi: 10.1016/j.ejps.2016.03.009.

PMID:
26972276
8.

PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.

Shroff K, Kokkoli E.

Langmuir. 2012 Mar 13;28(10):4729-36. doi: 10.1021/la204466g.

PMID:
22268611
9.

A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer.

Chang DK, Lin CT, Wu CH, Wu HC.

PLoS One. 2009;4(1):e4171. doi: 10.1371/journal.pone.0004171.

10.

A nanomedicine based combination therapy based on QLPVM peptide functionalized liposomal tamoxifen and doxorubicin against Luminal A breast cancer.

Wang X, Chen X, Yang X, Gao W, He B, Dai W, Zhang H, Wang X, Wang J, Zhang X, Dai Z, Zhang Q.

Nanomedicine. 2016 Feb;12(2):387-97. doi: 10.1016/j.nano.2015.12.360.

PMID:
26711969
11.

Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery.

Lu RM, Chang YL, Chen MS, Wu HC.

Biomaterials. 2011 Apr;32(12):3265-74. doi: 10.1016/j.biomaterials.2010.12.061.

PMID:
21306768
12.

PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.

Yang Y, Yang Y, Xie X, Cai X, Zhang H, Gong W, Wang Z, Mei X.

Biomaterials. 2014 May;35(14):4368-81. doi: 10.1016/j.biomaterials.2014.01.076.

PMID:
24565519
13.

Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.

Shahin M, Soudy R, Aliabadi HM, Kneteman N, Kaur K, Lavasanifar A.

Biomaterials. 2013 May;34(16):4089-97. doi: 10.1016/j.biomaterials.2013.02.019.

PMID:
23465829
14.

Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors.

Chang DK, Chiu CY, Kuo SY, Lin WC, Lo A, Wang YP, Li PC, Wu HC.

J Biol Chem. 2009 May 8;284(19):12905-16. doi: 10.1074/jbc.M900280200.

15.

Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation.

Alibolandi M, Abnous K, Sadeghi F, Hosseinkhani H, Ramezani M, Hadizadeh F.

Int J Pharm. 2016 Mar 16;500(1-2):162-78. doi: 10.1016/j.ijpharm.2016.01.040.

PMID:
26802496
16.

Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.

Moosavian SA, Abnous K, Badiee A, Jaafari MR.

Colloids Surf B Biointerfaces. 2016 Mar 1;139:228-36. doi: 10.1016/j.colsurfb.2015.12.009.

PMID:
26722819
17.

Tumor-targeted liposomal drug delivery mediated by a diseleno bond-stabilized cyclic peptide.

Li C, Wang Y, Zhang X, Deng L, Zhang Y, Chen Z.

Int J Nanomedicine. 2013;8:1051-62. doi: 10.2147/IJN.S40498.

18.

Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers.

Guo Z, He B, Yuan L, Dai W, Zhang H, Wang X, Wang J, Zhang X, Zhang Q.

Int J Pharm. 2015 Sep 30;493(1-2):380-9. doi: 10.1016/j.ijpharm.2015.05.051.

PMID:
26004003
19.

The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer.

Wang Z, Yu Y, Dai W, Lu J, Cui J, Wu H, Yuan L, Zhang H, Wang X, Wang J, Zhang X, Zhang Q.

Biomaterials. 2012 Nov;33(33):8451-60. doi: 10.1016/j.biomaterials.2012.08.031.

PMID:
22940213
20.

Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.

Gabizon A, Tzemach D, Gorin J, Mak L, Amitay Y, Shmeeda H, Zalipsky S.

Cancer Chemother Pharmacol. 2010 May;66(1):43-52. doi: 10.1007/s00280-009-1132-4.

PMID:
19779718

Supplemental Content

Support Center